Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies have?
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies has 61 citations in the OpenAlex counts ScholarIQ stores.
When was Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies published?
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies has 2021 year in the ScholarIQ index.
What is the open-access status of Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies?
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies has gold oa status in the ScholarIQ index.
What is the DOI of Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies?
The DOI for Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies is on the source record.
What is the PMID of Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies?
The PMID for Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies is on the source record.
What is the OpenAlex record for Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies?
The OpenAlex for Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies is on the source record.